Zdrowie i gospodarka · 21/01/2026
FDA Announces Draft Guidance for Industry on Minimal Residual Disease and Complete Response in Multiple Myeloma
The FDA is announcing the availability of a draft guidance for industry on using minimal residual disease (MRD) and complete response (CR) as endpoints to support accelerated approval for multiple myeloma treatments.